Multi-centre experience on the use of perhexiline in chronic heart failure and refractory angina: old drug, new hope

Thanh Trung Phan, Ganesh Nallur Shivu, Anirban Choudhury, Khalid Abozguia, Chris Davies, Ulasini Naidoo, Ibrar Ahmed, Zaheer Yousef, John Horowitz, Michael Frenneaux

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

The objective of this study is to report on our 5-year collective experience on the use of perhexiline in the UK, in patients with chronic heart failure (CHF) and/or refractory angina with respect to 'real-life' drug side effects and toxicity, therapeutic drug level monitoring, 5 year mortality outcomes and predictors of response to perhexiline therapy.

Data on clinical history, perhexiline monitoring, follow-up, and mortality were retrospectively collated from centralized perhexiline databases from two tertiary referral centres. A total of 151 patients were on perhexiline therapy at two UK tertiary referral centres. At 3-4 months, 68.8% of patients had drug level within the therapeutic range and 20.8% were above the therapeutic range. A total of 58.9% of patients reported to have felt better on the perhexiline (responders). The presence of refractory angina was an independent predictor of response to perhexiline therapy (odds ratio 2.84, 95% confidence interval 1.28-6.32, P = 0.01). Five-year mortality was non-significantly different between patients with refractory angina, CHF, or both (20.5, 31.0, and 38.4%, P = 0.20, respectively).

Perhexiline therapy provides symptomatic relief in the majority of patients with minimal side effects or toxicity. Careful therapeutic level monitoring for dose titration is important to prevent acute and chronic toxicity. Patients with refractory angina were more likely to be responders.

Original languageEnglish
Pages (from-to)881-886
Number of pages6
JournalEuropean Journal of Heart Failure
Volume11
Issue number9
DOIs
Publication statusPublished - Sep 2009

Keywords

  • chronic heart failure
  • refractory angina
  • perhexiline
  • mortality and drug monitoring
  • maleate
  • oxidation
  • creatine
  • pectoris
  • disease

Cite this

Phan, T. T., Shivu, G. N., Choudhury, A., Abozguia, K., Davies, C., Naidoo, U., ... Frenneaux, M. (2009). Multi-centre experience on the use of perhexiline in chronic heart failure and refractory angina: old drug, new hope. European Journal of Heart Failure, 11(9), 881-886. https://doi.org/10.1093/eurjhf/hfp106

Multi-centre experience on the use of perhexiline in chronic heart failure and refractory angina : old drug, new hope. / Phan, Thanh Trung; Shivu, Ganesh Nallur; Choudhury, Anirban; Abozguia, Khalid; Davies, Chris; Naidoo, Ulasini; Ahmed, Ibrar; Yousef, Zaheer; Horowitz, John; Frenneaux, Michael.

In: European Journal of Heart Failure, Vol. 11, No. 9, 09.2009, p. 881-886.

Research output: Contribution to journalArticle

Phan, TT, Shivu, GN, Choudhury, A, Abozguia, K, Davies, C, Naidoo, U, Ahmed, I, Yousef, Z, Horowitz, J & Frenneaux, M 2009, 'Multi-centre experience on the use of perhexiline in chronic heart failure and refractory angina: old drug, new hope', European Journal of Heart Failure, vol. 11, no. 9, pp. 881-886. https://doi.org/10.1093/eurjhf/hfp106
Phan, Thanh Trung ; Shivu, Ganesh Nallur ; Choudhury, Anirban ; Abozguia, Khalid ; Davies, Chris ; Naidoo, Ulasini ; Ahmed, Ibrar ; Yousef, Zaheer ; Horowitz, John ; Frenneaux, Michael. / Multi-centre experience on the use of perhexiline in chronic heart failure and refractory angina : old drug, new hope. In: European Journal of Heart Failure. 2009 ; Vol. 11, No. 9. pp. 881-886.
@article{a20fc5ef49fa422199aafb29ab529e14,
title = "Multi-centre experience on the use of perhexiline in chronic heart failure and refractory angina: old drug, new hope",
abstract = "The objective of this study is to report on our 5-year collective experience on the use of perhexiline in the UK, in patients with chronic heart failure (CHF) and/or refractory angina with respect to 'real-life' drug side effects and toxicity, therapeutic drug level monitoring, 5 year mortality outcomes and predictors of response to perhexiline therapy.Data on clinical history, perhexiline monitoring, follow-up, and mortality were retrospectively collated from centralized perhexiline databases from two tertiary referral centres. A total of 151 patients were on perhexiline therapy at two UK tertiary referral centres. At 3-4 months, 68.8{\%} of patients had drug level within the therapeutic range and 20.8{\%} were above the therapeutic range. A total of 58.9{\%} of patients reported to have felt better on the perhexiline (responders). The presence of refractory angina was an independent predictor of response to perhexiline therapy (odds ratio 2.84, 95{\%} confidence interval 1.28-6.32, P = 0.01). Five-year mortality was non-significantly different between patients with refractory angina, CHF, or both (20.5, 31.0, and 38.4{\%}, P = 0.20, respectively).Perhexiline therapy provides symptomatic relief in the majority of patients with minimal side effects or toxicity. Careful therapeutic level monitoring for dose titration is important to prevent acute and chronic toxicity. Patients with refractory angina were more likely to be responders.",
keywords = "chronic heart failure, refractory angina, perhexiline, mortality and drug monitoring, maleate, oxidation, creatine, pectoris, disease",
author = "Phan, {Thanh Trung} and Shivu, {Ganesh Nallur} and Anirban Choudhury and Khalid Abozguia and Chris Davies and Ulasini Naidoo and Ibrar Ahmed and Zaheer Yousef and John Horowitz and Michael Frenneaux",
year = "2009",
month = "9",
doi = "10.1093/eurjhf/hfp106",
language = "English",
volume = "11",
pages = "881--886",
journal = "European Journal of Heart Failure",
issn = "1388-9842",
publisher = "Oxford University Press",
number = "9",

}

TY - JOUR

T1 - Multi-centre experience on the use of perhexiline in chronic heart failure and refractory angina

T2 - old drug, new hope

AU - Phan, Thanh Trung

AU - Shivu, Ganesh Nallur

AU - Choudhury, Anirban

AU - Abozguia, Khalid

AU - Davies, Chris

AU - Naidoo, Ulasini

AU - Ahmed, Ibrar

AU - Yousef, Zaheer

AU - Horowitz, John

AU - Frenneaux, Michael

PY - 2009/9

Y1 - 2009/9

N2 - The objective of this study is to report on our 5-year collective experience on the use of perhexiline in the UK, in patients with chronic heart failure (CHF) and/or refractory angina with respect to 'real-life' drug side effects and toxicity, therapeutic drug level monitoring, 5 year mortality outcomes and predictors of response to perhexiline therapy.Data on clinical history, perhexiline monitoring, follow-up, and mortality were retrospectively collated from centralized perhexiline databases from two tertiary referral centres. A total of 151 patients were on perhexiline therapy at two UK tertiary referral centres. At 3-4 months, 68.8% of patients had drug level within the therapeutic range and 20.8% were above the therapeutic range. A total of 58.9% of patients reported to have felt better on the perhexiline (responders). The presence of refractory angina was an independent predictor of response to perhexiline therapy (odds ratio 2.84, 95% confidence interval 1.28-6.32, P = 0.01). Five-year mortality was non-significantly different between patients with refractory angina, CHF, or both (20.5, 31.0, and 38.4%, P = 0.20, respectively).Perhexiline therapy provides symptomatic relief in the majority of patients with minimal side effects or toxicity. Careful therapeutic level monitoring for dose titration is important to prevent acute and chronic toxicity. Patients with refractory angina were more likely to be responders.

AB - The objective of this study is to report on our 5-year collective experience on the use of perhexiline in the UK, in patients with chronic heart failure (CHF) and/or refractory angina with respect to 'real-life' drug side effects and toxicity, therapeutic drug level monitoring, 5 year mortality outcomes and predictors of response to perhexiline therapy.Data on clinical history, perhexiline monitoring, follow-up, and mortality were retrospectively collated from centralized perhexiline databases from two tertiary referral centres. A total of 151 patients were on perhexiline therapy at two UK tertiary referral centres. At 3-4 months, 68.8% of patients had drug level within the therapeutic range and 20.8% were above the therapeutic range. A total of 58.9% of patients reported to have felt better on the perhexiline (responders). The presence of refractory angina was an independent predictor of response to perhexiline therapy (odds ratio 2.84, 95% confidence interval 1.28-6.32, P = 0.01). Five-year mortality was non-significantly different between patients with refractory angina, CHF, or both (20.5, 31.0, and 38.4%, P = 0.20, respectively).Perhexiline therapy provides symptomatic relief in the majority of patients with minimal side effects or toxicity. Careful therapeutic level monitoring for dose titration is important to prevent acute and chronic toxicity. Patients with refractory angina were more likely to be responders.

KW - chronic heart failure

KW - refractory angina

KW - perhexiline

KW - mortality and drug monitoring

KW - maleate

KW - oxidation

KW - creatine

KW - pectoris

KW - disease

U2 - 10.1093/eurjhf/hfp106

DO - 10.1093/eurjhf/hfp106

M3 - Article

VL - 11

SP - 881

EP - 886

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

SN - 1388-9842

IS - 9

ER -